Reversible nonoliguric acute renal failure associated with zomepirac therapy

J. T. McCarthy, G. L. Schwartz, T. J. Blair, A. M. Pierides, C. J. Van den Berg

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Zomepirac sodium (Zomax) is a nonsteroidal anti-inflammatory agent with analgesic properties which was recently released for clinical use in this country. We report here a case of nonoliguric acute renal failure associated with zomepirac sodium therapy. This acute renal failure improved upon cessation of zomepirac treatment. Renal biopsy disclosed the presence of a tubulointerstitial nephritis, which was thought to have been responsible for the acute renal failure in this patient. Clinicians should be aware of the potential nephrotoxicity of zomepirac sodium and use caution in its administration, especially in patients with compromised intravascular volume status, hypertension, or preexistent chronic renal disease.

Original languageEnglish (US)
Pages (from-to)351-354
Number of pages4
JournalMayo Clinic proceedings
Volume57
Issue number6
StatePublished - Dec 1 1982

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Reversible nonoliguric acute renal failure associated with zomepirac therapy'. Together they form a unique fingerprint.

  • Cite this

    McCarthy, J. T., Schwartz, G. L., Blair, T. J., Pierides, A. M., & Van den Berg, C. J. (1982). Reversible nonoliguric acute renal failure associated with zomepirac therapy. Mayo Clinic proceedings, 57(6), 351-354.